However, the use of the second generation anti-CD19 CAR-T-cells with a costimulatory domain (4-1BB, CD28, and ICOS) in preclinical studies have shown considerable anti-tumor impacts in-vitro/in-vivo (141). This evidence concerns the gene CD28 and neoplasm.